Chimerix's Brincidofovir (CMX001) Selected for Two Oral Presentations at the 2014 BMT Tandem Meetings

Chimerix, Inc. , a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced two oral presentations related to its broad-spectrum investigational antiviral, brincidofovir , at the BMT Tandem Meetings being held February 26 - March 2, 2014 in Grapevine, Texas.

http://ift.tt/1p3fSOL